Stephen Liu/LinkedIn
Apr 21, 2025, 08:34
Stephen Liu: Engaging Discussion on TROP2 ADCs in NSCLC
Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on LinkedIn:
“Thanks to my colleagues in China for a very engaging discussion on TROP2 ADCs in NSCLC – a massive audience with thoughtful questions. When and where can we incorporate these agents? How do we position these vs amivantamab or AK112 (ivonescimab)? Best partners? Biomarkers?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 14:31
May 30, 2025, 13:19
May 30, 2025, 12:53
May 30, 2025, 12:46
May 30, 2025, 12:32